Nonalcoholic Fatty Liver Disease

BOSTON — In this exclusive video from The Liver Meeting 2019, Arun Sanyal, MD, professor of medicine at Virginia Commonwealth University, highlights new data on emerging therapeutics for nonalcoholic steatohepatitis presented at the meeting.

The FDA accepted the first new drug application for the treatment of liver fibrosis due to nonalcoholic steatohepatitis; Intercept announced that obeticholic acid, already approved for the treatment of primary biliary cholangitis under the brand Ocaliva, has a PDUFA date of March 26, 2020.

BOSTON — In this exclusive video from The Liver Meeting 2019, Vlad Ratziu, MD, PhD, professor of hepatology at Sorbonne University and Pitié-Salpêtrière Hospital, discusses his poster presentation on the diagnostic aspects of nonalcoholic steatohepatitis in patients with type 2 diabetes.

Elysium Health completed enrollment for a clinical trial designed to evaluate the efficacy of Basis, a combination of the company’s proprietary nicotinamide riboside and pterostilbene, on liver fat accumulation in adults with nonalcoholic fatty liver disease, according to a press release.

Dicerna Pharmaceuticals and Novo Nordisk announced an agreement to develop RNA interference therapies for liver-related cardiometabolic diseases, according to a press release.

BOSTON — In this exclusive video from The Liver Meeting 2019, Rosemary Wickowski, co-founder and chief operating officer of the Fatty Liver Foundation, addresses the liver disease community regarding the optimistic future for patients with nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.

BOSTON — In this exclusive video from The Liver Meeting 2019, Wayne Eskridge, founder and CEO of the Fatty Liver Foundation, discusses the foundation’s goals for patient advocacy and an upcoming study designed to assess asymptomatic individuals who self-selected for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis screening.

BOSTON — Treatment with MSDC-0602K safely produced positive effects on glycemic control along with consistent improvement in liver enzymes and noninvasive hepatic markers in patients with nonalcoholic steatohepatitis and type 2 diabetes, according to data presented at The Liver Meeting 2019.

BOSTON — Patients with non-alcoholic steatohepatitis treated with licogliflozin experienced dose-dependent improvement in alanine aminotransferase levels and other measures, according to study results presented at the Liver Meeting 2019.

LAS VEGAS — Liver fat volume can be reduced by bariatric surgery regardless of procedure type, although some liver enzymes may be affected differently by sleeve gastrectomy or Roux-en-Y gastric bypass, according to findings presented at ObesityWeek.